NICE TA406: untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. (Decision date - Oct 2016).
NICE TA422: previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. (Decision date - January 2017).
NICE TA529: for treating ROS1-positive advanced non-small-cell lung cancer. (NHSE commissioned). (Decision date - August 2018).
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
